Antiviral - CMV Infection

The classification phrase "Antiviral - CMV Infection" is an administrative and compendial formulary category rather than a single pharmacologic drug class, encompassing distinct antiviral agents indicated for the prevention and treatment of cytomegalovirus disease Clinically, they are primarily deployed to manage CMV viremia and tissue-invasive disease in solid organ and hematopoietic stem cell transplant recipients, treat CMV retinitis in immunocompromised individuals with HIV/AIDS, and manage ...

The classification phrase "Antiviral - CMV Infection" is an administrative and compendial formulary category rather than a single pharmacologic drug class, encompassing distinct antiviral agents indicated for the prevention and treatment of cytomegalovirus disease

The classification phrase "Antiviral - CMV Infection" is an administrative and compendial formulary category rather than a single pharmacologic drug class, encompassing distinct antiviral agents indicated for the prevention and treatment of cytomegalovirus disease

Members of this category include viral DNA polymerase inhibitors such as ganciclovir, valganciclovir, foscarnet, and cidofovir, as well as newer targeted therapies like the terminase inhibitor letermovir and the protein kinase pUL97 inhibitor maribavir These medications function by selectively disrupting viral replication, DNA packaging, or capsid assembly

Members of this category include viral DNA polymerase inhibitors such as ganciclovir, valganciclovir, foscarnet, and cidofovir, as well as newer targeted therapies like the terminase inhibitor letermovir and the protein kinase pUL97 inhibitor maribavir These medications function by selectively disrupting viral replication, DNA packaging, or capsid assembly

Members of this category include viral DNA polymerase inhibitors such as ganciclovir, valganciclovir, foscarnet, and cidofovir, as well as newer targeted therapies like the terminase inhibitor letermovir and the protein kinase pUL97 inhibitor maribavir These medications function by selectively disrupting viral replication, DNA packaging, or capsid assembly

Clinically, they are primarily deployed to manage CMV viremia and tissue-invasive disease in solid organ and hematopoietic stem cell transplant recipients, treat CMV retinitis in immunocompromised individuals with HIV/AIDS, and manage congenital infections

Clinically, they are primarily deployed to manage CMV viremia and tissue-invasive disease in solid organ and hematopoietic stem cell transplant recipients, treat CMV retinitis in immunocompromised individuals with HIV/AIDS, and manage congenital infections